Dravet Syndrome Market Report 2026

Dravet Syndrome Market Overview

• Dravet Syndrome market size has reached to $0.4 billion in 2025 • Expected to grow to $0.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: Impact Of Rising Neurological Disorders On The Growth Of The Market • Market Trend: Advancements In RNA-Based Precision Medicine Driving Innovation In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Dravet Syndrome Market?

Dravet syndrome refers to a rare and severe form of epilepsy that begins in infancy, characterized by prolonged and frequent seizures that are often resistant to treatment. It is used for studying genetic mutations in the SCN1A gene and developing targeted therapies to manage seizure activity and improve patient outcomes. The main treatment and management types of dravet syndrome are seizure medications, ketogenic diet, vagus nerve stimulation, and others. Seizure medications are medications used to prevent or reduce the frequency and severity of seizures in conditions like epilepsy and other neurological disorders. Along with these treatments, there are different diagnostic tests such as magnetic resonance imaging testing, electroencephalography testing, sodium voltage-gated channel alpha subunit 1 testing, and others, and various routes of administration include parenteral routes, oral routes, and others. The multiple end users are pharmaceutical companies, hospitals, diagnostic laboratories, and academic and research institutes.

What Is The Dravet Syndrome Market Growth Forecast?

The dravet syndrome market size is expected to see strong growth in the next few years. It will grow to $0.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to gene therapy research, precision neurology treatments, early genetic screening, patient registry expansion, supportive care innovation. Major trends in the forecast period include growing development of targeted antiepileptic drugs, rising use of genetic testing for diagnosis, increased focus on rare disease therapies, adoption of cannabidiol-based treatments, expansion of multidisciplinary care models.

Global Dravet Syndrome Market Segmentation

1) By Treatment And Management: Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation, Other Treatments And Managements 2) By Diagnosis: Magnetic Resonance Imaging Testing, Electroencephalography Testing, Sodium Voltage-Gated Channel Alpha Subunit 1 Testing, Other Diagnosis 3) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administrations 4) By End-User: Pharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Other End-Users Subsegments: 1) By Seizure Medications: Anticonvulsants, Benzodiazepines, Levetiracetam, Cannabidiol (CBD) Based Medications, Topiramate, Lamotrigine 2) By Ketogenic Diet: Standard Ketogenic Diet (SKD), Modified Atkins Diet (MAD), Low Glycemic Index Treatment (LGIT), MCT (Medium Chain Triglyceride) Diet 3) By Vagus Nerve Stimulation: Implantable Vagus Nerve Stimulator (VNS), Non-Invasive Vagus Nerve Stimulation (NIVNS), Adjunct Therapy With VNS For Seizure Control 4) By Other Treatments And Managements: Physical and Occupational Therapy, Speech Therapy, Epilepsy Surgery, Cognitive Behavioral Therapy (CBT), Genetic Counseling And Support

What Is The Driver Of The Dravet Syndrome Market?

The rising prevalence of neurological disorders is expected to propel the growth of the Dravet syndrome market going forward. Neurological disorders refer to conditions that affect the brain, spinal cord, and nervous system, resulting in impairments in cognition, movement, sensation, and overall neurological function. The prevalence of neurological disorders is increasing due to aging populations, lifestyle changes, environmental factors, enhanced diagnostic capabilities, and rising rates of autoimmune and infectious neurological conditions. The dravet syndrome supports this trend by advancing research on genetic mutations, neuronal excitability, and targeted therapies that contribute to broader neurological-disease innovation. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, with projections indicating this could rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the Dravet syndrome industry.

Key Players In The Global Dravet Syndrome Market

Major companies operating in the dravet syndrome market are Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, H. Lundbeck A/S, BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Zogenix Inc., Biocodex S.A., Encoded Therapeutics Inc., Marinus Pharmaceuticals Inc., Arvelle Therapeutics GmbH, Stoke Therapeutics Inc., Longboard Pharmaceuticals Inc., Xenon Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., GW Pharmaceuticals plc, Ovid Therapeutics Inc.

Global Dravet Syndrome Market Trends and Insights

Major companies operating in the Dravet syndrome market are focusing on advances in precision medicine, such as RNA-based therapies, to develop targeted treatments that address the underlying genetic mutations driving the disorder, thereby improving efficacy and reducing side effects. RNA-based therapies refer to treatments that use RNA molecules to modulate gene expression or protein production, enabling correction of molecular defects at the source rather than only managing symptoms. For instance, in December 2024, Stoke Therapeutics Inc., a US-based biotechnology company, received U.S. FDA approval for zorevunersen for the treatment of Dravet syndrome, a therapy designed to increase expression of the SCN1A gene commonly mutated in patients with the condition thereby addressing the root genetic deficiency. By leveraging RNA-based precision medicine to restore proper neuronal function, zorevunersen has the potential to reduce seizure frequency and improve cognitive outcomes, representing a major advancement in targeted Dravet syndrome therapeutics.

What Are Latest Mergers And Acquisitions In The Dravet Syndrome Market?

In April 2024, Harmony Biosciences, a US-based pharmaceutical company, acquired Epygenix Therapeutics Inc. for an undisclosed amount. Through this acquisition, Harmony Biosciences aims to expand its rare epilepsy portfolio by integrating Epygenix’s lead candidate, EPX-100, which is being developed for Dravet syndrome and Lennox-Gastaut syndrome. Epygenix Therapeutics Inc. is a US-based biotechnology company that provides development of drugs for Dravet Syndrome

Regional Outlook

North America was the largest region in the dravet syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Dravet Syndrome Market?

The dravet syndrome market consists of revenues earned by entities that provide services such as advanced genetic screening, medical consultation and diagnosis, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The dravet syndrome market also includes sales of genetic testing kits, anticonvulsant medications, and emerging gene therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dravet Syndrome Market Report 2026?

The dravet syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dravet syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.